Atypical Tenosynovial Giant Cell Tumor of the Extensor Hallucis Longus Tendon

2006 ◽  
Vol 96 (4) ◽  
pp. 359-361 ◽  
Author(s):  
Keiichi Muramatsu ◽  
Takatomo Mine ◽  
Kazuhiko Ichihara

We present a case of atypical giant cell tumor of the tendon sheath originating from the extensor hallucis longus tendon. The tumor contained multiple nodules and overlay the tendon 16 cm. Magnetic resonance imaging was the most useful preoperative investigation and showed the characteristic appearance of giant cell tumor of the tendon sheath, thus allowing local excision to be planned and executed. We discuss how local recurrence of this tumor could be prevented. (J Am Podiatr Med Assoc 96(4): 359–361, 2006)

2020 ◽  
Vol 10 (2) ◽  
pp. e0519-e0519
Author(s):  
Richard D. Williams ◽  
M. Wesley Honeycutt ◽  
Elizabeth A. Manci ◽  
Prasit Nimityongskul

2011 ◽  
Vol 101 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Jeff Findling ◽  
Natalie K. LaScola ◽  
Thomas W. Groner

Giant cell tumor of tendon sheath is infrequently documented in the foot and even less near the ankle. This case report involves such a tumor of the flexor hallucis longus tendon presenting at the posterior ankle. Diagnosis was aided by magnetic resonance imaging, and treatment consisted of complete surgical excision. Pathologic examination verified the diagnosis of giant cell tumor of tendon sheath, and follow-up magnetic resonance imaging revealed no remnants or recurrence of tumor 1 year after surgery. (J Am Podiatr Med Assoc 101(2): 187–189, 2011)


2018 ◽  
Vol 12 (4) ◽  
pp. 352-55
Author(s):  
Anderson Humberto Gomes ◽  
Bruno Janotti Pádua ◽  
Luiz Eduardo Moreira Teixeira ◽  
Claudio Beling Gonçalves Soares

In this study, we report the case of a patient with a lobulated expansile lesion of 16.6 cm in its largest diameter, who was referred as having a simple “synovial cyst” in the foot that actually was a giant cell tumor of the tendon sheath along the extensor hallucis longus. Conducting a differential diagnosis of a “synovial cyst” in the foot and ankle, performing adequate surgical planning and using imaging tests, such as nuclear magnetic resonance, increases the probability of treatment success. Level of Evidence V; Therapeutic Studies; Expert Opinion.


2017 ◽  
Vol 13 (6) ◽  
pp. 4459-4462 ◽  
Author(s):  
Chao Wang ◽  
Rui-Rui Song ◽  
Ping-Ding Kuang ◽  
Liu-Hong Wang ◽  
Min-Ming Zhang

2020 ◽  
Vol 16 (25) ◽  
pp. 1875-1878 ◽  
Author(s):  
William Tap

Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at pexidartinib (brand name, Turalio™), a medication taken by mouth (orally) for people with TGCT (also known as giant cell tumor of the tendon sheath [GCTTS] and pigmented villonodular synovitis [PVNS]) who are not able to have surgery because of the location and/or the size of the tumor. The study showed that pexidartinib is effective in treating people with TGCT because it shrunk the size of their tumors and improved their symptoms and their ability to function. In general, people treated with pexidartinib had side effects that were mostly mild that went away after treatment with pexidartinib was stopped. The most common side effects were hair color changes and tiredness (fatigue). Pexidartinib was also associated with liver problems (or hepatotoxicity), which started within the first 2 months of treatment. Due to the risk of liver problems, which may be severe and potentially life threatening, the researchers closely monitored participants’ blood liver function tests before, during, and after participants in the study took pexidartinib. To read the full Plain Language Summary of this article, click on the View Article button above and download the PDF. Clinical Trial Registration: NCT02371369 ( ClinicalTrials.gov )


2017 ◽  
Vol 107 (4) ◽  
pp. 333-336 ◽  
Author(s):  
Michael Levi ◽  
Jordan Crafton

Giant-cell tumor of the tendon sheath (GCT-TS) is an uncommon occurrence for a foot and ankle surgeon. However, there is a need to recognize the symptoms of typical and atypical presentations of this pathology. These benign neoplasms are recognized clinically as a soft-tissue mass that is usually painless and palpable. The foot and ankle account for only 3% to 5% of all GCT-TS in the body, with most being located in the hand. Giant cell tumor in the tendon sheath occurring in the foot and ankle is usually encountered on the lateral ankle and dorsum of the foot, occupying the extensor tendons. Additionally, it is commonly misdiagnosed clinically. This case study illustrates how early use of magnetic resonance imaging decreased patient morbidity with early recognition and excision of GCT-TS.


2000 ◽  
Vol 44 (3) ◽  
pp. 463-466 ◽  
Author(s):  
Monisha Choudhury ◽  
Renu Jain ◽  
Anita Nangia ◽  
K.B. Logani

Sign in / Sign up

Export Citation Format

Share Document